Oncology

Personalised therapy allows patients with various types of cancer to prolong and improve their quality of life. To effectively set up the therapy, it is necessary to distinguish patients who will benefit from treatment from patients whose cancer is naturally resistant to the therapy.

The appropriate predictive molecular markers can increase the overall effectiveness and reduce the financial costs of the therapy.
Knowledge about the mutation status of RAS genes, EGFR, IDH1, IDH2, PIK3CA, POLE/CTNNB1, TERT and TP53 genes is required to indicate the proper treatment of metastatic carcinomas and to assess the disease prognosis.

Download fastGEN oncology leaflet